Tesaro's PARP Inhibitor Enters Phase III Testing
Tesaro Inc., of Waltham, Mass., advanced its poly ADP-ribose polymerase (PARP) inhibitor, niraparib, for ovarian cancer into a Phase III. The double-blind, placebo-controlled trial, designated NOVA, began enrollment of patients with high-grade serous, platinum-sensitive, relapsed ovarian cancer.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST